BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 36370151)

  • 1. Exosome-transmitted S100A4 induces immunosuppression and non-small cell lung cancer development by activating STAT3.
    Wu X; Zhang H; Jiang G; Peng M; Li C; Lu J; Jiang S; Yang X; Jiang Y
    Clin Exp Immunol; 2022 Dec; 210(3):309-320. PubMed ID: 36370151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer.
    Xie C; Zhou X; Liang C; Li X; Ge M; Chen Y; Yin J; Zhu J; Zhong C
    J Exp Clin Cancer Res; 2021 Aug; 40(1):266. PubMed ID: 34429133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bu Fei Decoction attenuates the tumor associated macrophage stimulated proliferation, migration, invasion and immunosuppression of non-small cell lung cancer, partially via IL-10 and PD-L1 regulation.
    Pang L; Han S; Jiao Y; Jiang S; He X; Li P
    Int J Oncol; 2017 Jul; 51(1):25-38. PubMed ID: 28534943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 5. MicroRNA-4458 Regulates PD-L1 Expression to Enhance Anti-tumor Immunity in NSCLC via Targeting STAT3.
    Liu W; Liu R; Yuan R; Wang X
    Mol Biotechnol; 2021 Dec; 63(12):1268-1279. PubMed ID: 34386930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exosome-transmitted lncRNA UFC1 promotes non-small-cell lung cancer progression by EZH2-mediated epigenetic silencing of PTEN expression.
    Zang X; Gu J; Zhang J; Shi H; Hou S; Xu X; Chen Y; Zhang Y; Mao F; Qian H; Zhu T; Xu W; Zhang X
    Cell Death Dis; 2020 Apr; 11(4):215. PubMed ID: 32242003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exosomal S100A4 derived from highly metastatic hepatocellular carcinoma cells promotes metastasis by activating STAT3.
    Sun H; Wang C; Hu B; Gao X; Zou T; Luo Q; Chen M; Fu Y; Sheng Y; Zhang K; Zheng Y; Ren X; Yan S; Geng Y; Yang L; Dong Q; Qin L
    Signal Transduct Target Ther; 2021 May; 6(1):187. PubMed ID: 34035222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanistic Insights of Anti-Immune Evasion by Nobiletin through Regulating miR-197/STAT3/PD-L1 Signaling in Non-Small Cell Lung Cancer (NSCLC) Cells.
    Sp N; Kang DY; Lee JM; Jang KJ
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1/p-STAT3 promotes the progression of NSCLC cells by regulating TAM polarization.
    Zhang R; Meng Z; Wu X; Zhang M; Piao Z; Jin T
    J Cell Mol Med; 2022 Dec; 26(23):5872-5886. PubMed ID: 36372977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circular RNA circ-CPA4/ let-7 miRNA/PD-L1 axis regulates cell growth, stemness, drug resistance and immune evasion in non-small cell lung cancer (NSCLC).
    Hong W; Xue M; Jiang J; Zhang Y; Gao X
    J Exp Clin Cancer Res; 2020 Aug; 39(1):149. PubMed ID: 32746878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of galectin-3 augments the antitumor efficacy of PD-L1 blockade in non-small-cell lung cancer.
    Zhang H; Liu P; Zhang Y; Han L; Hu Z; Cai Z; Cai J
    FEBS Open Bio; 2021 Mar; 11(3):911-920. PubMed ID: 33455075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. S100A4 drives non-small cell lung cancer invasion, associates with poor prognosis, and is effectively targeted by the FDA-approved anti-helminthic agent niclosamide.
    Stewart RL; Carpenter BL; West DS; Knifley T; Liu L; Wang C; Weiss HL; Gal TS; Durbin EB; Arnold SM; O'Connor KL; Chen M
    Oncotarget; 2016 Jun; 7(23):34630-42. PubMed ID: 27127879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-140 Expression Regulates Cell Proliferation and Targets PD-L1 in NSCLC.
    Xie WB; Liang LH; Wu KG; Wang LX; He X; Song C; Wang YQ; Li YH
    Cell Physiol Biochem; 2018; 46(2):654-663. PubMed ID: 29617683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ezrin regulates the progression of NSCLC by YAP and PD-L1.
    Bu F; Zhang Y; Zhao N; Tian X; Xu Y
    Clin Transl Oncol; 2023 Jul; 25(7):2239-2249. PubMed ID: 36795259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-185-5p targets RAB35 gene to regulate tumor cell-derived exosomes-mediated proliferation, migration and invasion of non-small cell lung cancer cells.
    Wen H; Liu Z; Tang J; Bu L
    Aging (Albany NY); 2021 Sep; 13(17):21435-21450. PubMed ID: 34500436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EPN3 plays oncogenic role in non-small cell lung cancer by activating the JAK1/2-STAT3 pathway.
    Meng J; Zhang C; Zhu N; Zhang C; Liu M; Han Z; Li Y
    Environ Toxicol; 2023 Aug; 38(8):1968-1979. PubMed ID: 37186036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients.
    Li C; Li C; Zhi C; Liang W; Wang X; Chen X; Lv T; Shen Q; Song Y; Lin D; Liu H
    J Transl Med; 2019 Oct; 17(1):355. PubMed ID: 31665020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer.
    Kim DH; Kim H; Choi YJ; Kim SY; Lee JE; Sung KJ; Sung YH; Pack CG; Jung MK; Han B; Kim K; Kim WS; Nam SJ; Choi CM; Yun M; Lee JC; Rho JK
    Exp Mol Med; 2019 Aug; 51(8):1-13. PubMed ID: 31399559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha5 nicotinic acetylcholine receptor mediated immune escape of lung adenocarcinoma via STAT3/Jab1-PD-L1 signalling.
    Zhu P; Jin Z; Kang G; Jia Y; Liu D; Zhang Q; Guo F; Jia Y; Jiao Y; Li J; Sun H; Ma X
    Cell Commun Signal; 2022 Aug; 20(1):121. PubMed ID: 35971127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-210 transferred by lung cancer cell-derived exosomes may act as proangiogenic factor in cancer-associated fibroblasts by modulating JAK2/STAT3 pathway.
    Fan J; Xu G; Chang Z; Zhu L; Yao J
    Clin Sci (Lond); 2020 Apr; 134(7):807-825. PubMed ID: 32219336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.